Lucero Bio
@lucerobio.com
We are a bioconvergence company that weds synergistic technologies from the fields of microbiology, AI, and microfluidics. Our solution aims to tackle key challenges surrounding 3D-cell-culture handling, miniaturization, and assay preparation. Lucero’s platform will enable pharmaceutical companies to reliably use 3D cell cultures at scale to make faster pipeline decisions and accelerate promising candidates to the clinic.
Lucero Bio's Company Logos
Lucero Bio's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FA8B2E
Crusta
250, 139, 46
27, 95, 58
0, 44, 82, 2
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#023834
Sherwood Green
2, 56, 52
176, 93, 11
96, 0, 7, 78
About Lucero Bio
Lucero Bio is a bioconvergence company founded in March 2020 in Gothenburg, Sweden. With expertise in photonics, AI, microbiology, and laser optics, Lucero is dedicated to accelerating the discovery of personalized drugs and treatments. Their innovative platform addresses the challenges of implementing 3D cell cultures in early-stage pharmaceutical drug discovery processes.
By combining cutting-edge technologies, Lucero aims to improve 3D-cell-culture handling, miniaturization, and assay preparation. They believe that a better understanding of the underlying mechanistic biology of drug response is essential for personalized medicine. However, a key obstacle to using 3D cell cultures at scale in established pharmaceutical workflows remains.
Lucero's platform offers a solution by enabling pharmaceutical companies to reliably use 3D cell cultures, resulting in faster pipeline decisions and the acceleration of promising candidates to the clinic. With a team of experienced co-founders and advisors, Lucero Bio is at the forefront of precision 3D cell culture handling
Company type
Privately Held
Year founded
2020
Company size
2-10 employees
